News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announced a private placement of convertible promissory notes to selected investors for working capital. H.C. Wainwright & Co. is the placement agent -
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 at AACR, showcasing potential to enhance immune checkpoint inhibitors' efficacy -
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Xenetic Biosciences, Inc. collaborates with PeriNess Ltd. on a clinical study at Tel-Aviv Sourasky Medical Center to evaluate DNase I candidate XBIO-015 in osteosarcoma and Ewing sarcoma patients -
-
COMMUNIQUÉ DE PRESSE
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
Applied DNA Sciences' ADCL seeks NYSDOH approval for PCR-based assay to detect H5 bird flu, leveraging PCR-based DNA technologies. Development initiated due to health concerns -
COMMUNIQUÉ DE PRESSE
ALT5 Sigma to Exhibit at Transact Las Vegas April 2-4, 2025
ALT5 Sigma Corp. (NASDAQ:ALTS) to showcase blockchain-powered fintech solutions at Transact Las Vegas alongside key players in payments ecosystem. Event focuses on innovations in payment processing, digital assets, and blockchain -
